Compare CYTK & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | HIMS |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.9B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | HIMS |
|---|---|---|
| Price | $62.41 | $31.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 12 |
| Target Price | ★ $82.38 | $44.90 |
| AVG Volume (30 Days) | 2.2M | ★ 12.2M |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.76 |
| EPS | N/A | ★ 0.54 |
| Revenue | $87,211,000.00 | ★ $2,210,958,000.00 |
| Revenue This Year | $346.43 | $62.27 |
| Revenue Next Year | $57.69 | $18.20 |
| P/E Ratio | ★ N/A | $59.03 |
| Revenue Growth | ★ 2609.26 | 78.02 |
| 52 Week Low | $29.31 | $23.97 |
| 52 Week High | $70.98 | $72.98 |
| Indicator | CYTK | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 35.33 |
| Support Level | $62.05 | $32.05 |
| Resistance Level | $66.59 | $36.45 |
| Average True Range (ATR) | 2.97 | 1.48 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 33.47 | 0.16 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.